209 related articles for article (PubMed ID: 17276949)
21. Myxoid adrenocortical neoplasms: a study of the clinicopathologic features and EGFR gene status of ten Chinese cases.
Zhang J; Sun J; Liang Z; Gao J; Zeng X; Liu T
Am J Clin Pathol; 2011 Nov; 136(5):783-92. PubMed ID: 22031318
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumors in children.
Chatterjee G; DasGupta S; Mukherjee G; Sengupta M; Roy P; Arun I; Datta C; Mishra PK; Banerjee S; Chatterjee U
Pediatr Surg Int; 2015 Jun; 31(6):563-71. PubMed ID: 25895073
[TBL] [Abstract][Full Text] [Related]
23. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
[TBL] [Abstract][Full Text] [Related]
24. Myxoid adrenal cortical neoplasms.
Raparia K; Ayala AG; Sienko A; Zhai QJ; Ro JY
Ann Diagn Pathol; 2008 Oct; 12(5):344-8. PubMed ID: 18774497
[TBL] [Abstract][Full Text] [Related]
25. [Comparative clinical analysis of histological systems of adrenocortical tumors diagnosis].
Bokhyan VY; Stilidi IS; Pavlovskaya AI
Vopr Onkol; 2015; 61(6):925-31. PubMed ID: 26995980
[TBL] [Abstract][Full Text] [Related]
26. Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas.
Pennanen M; Heiskanen I; Sane T; Remes S; Mustonen H; Haglund C; Arola J
Hum Pathol; 2015 Mar; 46(3):404-10. PubMed ID: 25582500
[TBL] [Abstract][Full Text] [Related]
27. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
Sturgeon C; Shen WT; Clark OH; Duh QY; Kebebew E
J Am Coll Surg; 2006 Mar; 202(3):423-30. PubMed ID: 16500246
[TBL] [Abstract][Full Text] [Related]
28. Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma.
Mondal SK; Dasgupta S; Jain P; Mandal PK; Sinha SK
J Cancer Res Ther; 2013; 9(3):436-41. PubMed ID: 24125979
[TBL] [Abstract][Full Text] [Related]
29. Cytological features of myxoid adrenocortical adenoma with a pseudoglandular component: a case report with differential diagnostic considerations.
Ishida M; Yoshida K; Miyamoto K; Iwai M; Miyahira Y; Kushima R; Okabe H
Diagn Cytopathol; 2008 Aug; 36(8):576-80. PubMed ID: 18618725
[TBL] [Abstract][Full Text] [Related]
30. Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study.
Pinzani P; Scatena C; Salvianti F; Corsini E; Canu L; Poli G; Paglierani M; Piccini V; Pazzagli M; Nesi G; Mannelli M; Luconi M
J Clin Endocrinol Metab; 2013 Sep; 98(9):3731-8. PubMed ID: 23836937
[TBL] [Abstract][Full Text] [Related]
31. Pediatric adrenocortical tumors: morphological diagnostic criteria and immunohistochemical expression of matrix metalloproteinase type 2 and human leucocyte-associated antigen (HLA) class II antigens. Results from the Italian Pediatric Rare Tumor (TREP) Study project.
Magro G; Esposito G; Cecchetto G; Dall'Igna P; Marcato R; Gambini C; Boldrini R; Collini P; D'Onofrio V; Salfi N; d'Amore E; Ferrari A; Bisogno G; Alaggio R
Hum Pathol; 2012 Jan; 43(1):31-9. PubMed ID: 21820153
[TBL] [Abstract][Full Text] [Related]
32. The molecular basis of adrenocortical cancer.
Lehmann T; Wrzesinski T
Cancer Genet; 2012 Apr; 205(4):131-7. PubMed ID: 22559973
[TBL] [Abstract][Full Text] [Related]
33. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
34. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.
Mete O; Erickson LA; Juhlin CC; de Krijger RR; Sasano H; Volante M; Papotti MG
Endocr Pathol; 2022 Mar; 33(1):155-196. PubMed ID: 35288842
[TBL] [Abstract][Full Text] [Related]
35. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.
Bilimoria KY; Shen WT; Elaraj D; Bentrem DJ; Winchester DJ; Kebebew E; Sturgeon C
Cancer; 2008 Dec; 113(11):3130-6. PubMed ID: 18973179
[TBL] [Abstract][Full Text] [Related]
36. Computed tomography (CT) scan identified necrosis, but is it a reliable single parameter for discerning between malignant and benign adrenocortical tumors?
Garay-Lechuga D; Pérez-Soto RH; Hernández-Acevedo JD; Butrón-Hernández D; Sierra-Salazar M; Pantoja-Millán JP; Herrera MF; Velázquez-Fernández D
Surgery; 2022 Jan; 171(1):104-110. PubMed ID: 34183180
[TBL] [Abstract][Full Text] [Related]
37. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
38. Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry.
Dalino Ciaramella P; Vertemati M; Petrella D; Bonacina E; Grossrubatscher E; Duregon E; Volante M; Papotti M; Loli P
Pathol Res Pract; 2017 Jul; 213(7):815-823. PubMed ID: 28554744
[TBL] [Abstract][Full Text] [Related]
39. Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors?
Pohlink C; Tannapfe A; Eichfeld U; Schmidt F; Führer D; Paschke R; Koch CA
J Endocrinol Invest; 2004 Jun; 27(6):565-9. PubMed ID: 15717655
[TBL] [Abstract][Full Text] [Related]
40. [Ultrastructural criteria of clinical prognosis in hormonally non-active adrenocortical tumors].
Raĭkhlin NT; Baronin AA; Smirnova EA; Probatova NA; Bronsteĭn MI; Bukaeva IA
Vopr Onkol; 2003; 49(1):44-50. PubMed ID: 12715369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
